PD-L1 Protein (AA 19-238) (His tag)

Catalog No. ABIN2181639

Recombinant PD-L1 protein expressed in HEK-293 Cells and has been mentioned in 6+ publications.

Quick Overview for PD-L1 Protein (AA 19-238) (His tag) (ABIN2181639)

Target: PD-L1 (CD274 (PD-L1))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: >98 % as determined by SDS-PAGE.

Grade: HPLC verified

Product Details

Protein Characteristics: AA 19-238

Purification tag / Conjugate: This PD-L1 protein is labelled with His tag.

Sequence: AA 19-238

Characteristics: This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 26 kDa. The protein migrates as 35-42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

References

Li, Ren, Zhao, Lou: "PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging." in: The Analyst, Vol. 146, Issue 9, pp. 2910-2918, (2021) (PubMed).

Lu, Xue, Deng, Zhou, Yu, Deng, Huang, Yi, Liang, Wang, Shen, Tong, Wang, Li, Song, Li, Su, Ding, Gong, Zhu, Wang, Zou, Zhang, Li, Zhou, Liu, Yu, Wang, Zhang, Yin, Xia, Zeng, Zhou, Ying, Chen, Wei, Li et al.: "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. ..." in: Nature medicine, Vol. 26, Issue 5, pp. 732-740, (2020) (PubMed).

Wang, Ni, Zhou, He, Gao, Wu, Wu, Wu, Qiu, Zhou, Chen, Pan, Huang, Li, Bian, Yang, Miao, Liu: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).

Chen, Xu, Du, Hou, Fan, Wu, Yan: "Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair." in: Neurochemical research, Vol. 44, Issue 11, pp. 2470-2481, (2019) (PubMed).

Fromm, de Silva, Johannes, Patel, Hornblower, Schreiber: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." in: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).

Lai, Huang, Wang, Lin, Yang: "A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects." in: Molecular therapy. Nucleic acids, Vol. 5, Issue 12, pp. e397, (2016) (PubMed).

Target Details

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PD-L1

Background: Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Molecular Weight: 26.0 kDa

NCBI Accession: NP_054862

Pathways: Cancer Immune Checkpoints